GATA3 and breast carcinoma: To dissect the impact of GATA3 mutations in breast cancer properties, we decided to focus on ZnFn2 mutations, because (1) gene expression profiles of established luminal breast cancer cell lines are known to be classified into the luminal B subtype26, and the ZnFn2 mutation group is the only group that is significantly frequently classified as luminal B; (2) the ZnFn2 mutations are associated with poor clinical outcomes.